Leukemia Research
Volume 33, Issue 12 , Pages 1627-1635 , December 2009

Pronostic significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature

  • Semra Paydas

      Affiliations

    • Department of Oncology, Cukurova University Faculty of Medicine, 01330 Adana, Turkey
    • Corresponding Author InformationCorresponding author. Tel.: +90 322 3386060; fax: +90 322 3386153.
    • ,
  • Melek Ergin

      Affiliations

    • Department of Pathology, Cukurova University Faculty of Medicine, 01330 Adana, Turkey
    • ,
  • Gulsah Seydaoglu

      Affiliations

    • Department of Biostatistics, Cukurova University Faculty of Medicine, 01330 Adana, Turkey
    • ,
  • Seyda Erdogan

      Affiliations

    • Department of Pathology, Cukurova University Faculty of Medicine, 01330 Adana, Turkey
    • ,
  • Sinan Yavuz

      Affiliations

    • Department of Oncology, Cukurova University Faculty of Medicine, 01330 Adana, Turkey

Received 11 January 2009 ,Revised 11 February 2009 ,Accepted 14 February 2009.

References 

  1. Paepe PD, Wolf-Peeters CD. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin's lymphomas comprising several distinct clinicopathological entities. Leukemia. 2007;21:37–43
  2. Paydas S, Ergin M, Erdogan S, Seydaoglu G, Yavuz S, Disel U. Trombospondin-1 (TSP-1) and survivin (S) expression in non-Hodgkin's lymphomas. Leuk Res. 2008;32:243–250
  3. Paydas S, Ergin M, Erdogan S, Seydaoglu G. Prognostic significance of EBV-LMP-1 and VEGF-A expressions in non-Hodgkin's lymphomas. Leuk Res. 2008;32:1424–1430
  4. Paydas S, Ergin M, Erdogan S, Seydaoglu G. Cylooxygenase-2 expression in non-Hodgkin's lymphomas. Leuk Lymphoma. 2007;48:389–395
  5. Paydas S, Seydaoglu G, Ergin M, Erdogan S. Prognostic significance of VEGF-A and VEGF-C in non-Hodgkin's lymphomaa and review of the literature. Leuk Lymphoma; in press.
  6. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with surviving. Cancer Sci. 2008;99:1709–1714
  7. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917–921
  8. Xiang XJ, He YJ, Li YH, Huang H, Xu F. Clinical significance of survivin expression in peripheral T-cell lymphoma. Ai Zheng. 2006;25:758–761
  9. Xiang XJ, He YJ. Clinical significance of survivin and caspase-3 expression in diffuse large B-cell lymphoma. Zhonghua Zhong Liu Za Zhi. 2006;28:298–301
  10. Li JF, Li GD, Liu WP, Wang Y, Cheng JR, Chen Y, et al. Expression of anaplastic lymphoma kinase and survivin proteins in anaplastic large cell lymphoma and its significance. Zhonghua Bing Li Xue Za Zhi. 2006;35:213–217
  11. Schlette EJ, Mederios LJ, Goy A, Lai R, Rassidakis GZ. Survivin expression predicts poorer prognosis in anaplastic large cell lymphoma. J Clin Oncol. 2004;22:1682–1688
  12. Zuo XL, Zhou X, Meng J, Zhang KJ, Liu XH, Yang HQ. A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin's lymphoma. Zhonghua Nei Ke Za Zhi. 2006;45:133–135
  13. Adida C, Haioun C, Gaulard P, Lepage E, Morel P, Briere J, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–1925
  14. Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Deconinck E, Mougin C, et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia. 2002;16(4):726–735
  15. Troeger A, Siepermann M, Escherich G, Meisel R, Willers R, Gudowius S, et al. Survivin and its prognostic significance in pediatric acute lymphoblastic leukemia. Haematologica. 2007;92:1043–1050
  16. Romagnoli M, Trichet V, David C, Clement M, Moreau P, Batallie R, et al. Significant impact of survivin on myeloma cell growth. Leukemia. 2007;21:1070–1078
  17. Liu L, Zhang M, Zou P. Expression of PLK1 and survivin in diffuse large B-cell lymphoma. Leuk Lymphoma. 2007;48:2179–2183
  18. Caldas H, Fangusaro JR, Boue DR, Holloway MP, Altura RA. Dissecting the role of endothelial survivin Ex3 in angiogenesis. Blood. 2007;109:1479–1489
  19. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000–5005
  20. Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Deconinck E, Mougin C, et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia. 2002;16:726–735
  21. Watanuki-Miyauchi R, Kojima Y, Tsurumi H, Hara T, Goto N, Kasahara S, et al. Expression of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. Pathol Int. 2005;55:324–330
  22. Mainou-Fowler T, Overman LM, Dignum H, Wood K, Crosier S, Angus B, et al. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol. 2008;32:59–68
  23. Tracey L, Perez-Rosado A, Artiga MJ, Camacho F, Rodriguez A, Martinez N, et al. Expression of the NF-k B targets BCL2 and BIRC5/survivin characterizes small B cell and aggressive B-cell lymphomas, respectively. J Pathol. 2005;206:123–134
  24. Martinez A, Bellesillo B, Bosch F, Ferrer A, Marce S, Villamor N, et al. Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol. 2004;164:501–510
  25. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and molecular regulation. Nat Med. 1995;1:27–31
  26. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh I, Cao Y, et al. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 1997;16:3898–3911
  27. Ellis I, Filde I. Angiogenesis and metastasis. Eur J Cancer. 1996;32A:2451–2460
  28. Beck LJ, D’Amore P. Vascular development: cellular and molecular regulation. FASEB J. 1997;11:365–373
  29. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–2049
  30. Zhang XH, Huang DP, Guo GL, Chen GR, Zhang HX, Wan L, et al. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer. 2008;8:4
  31. Mohammed RAA, Green A, El-Shikh S, Paish EC, Ellis IO, Martin SG. Prognostic significance of vascular endothelial cell growth factors-A, C, and–D in breast cancer and their relationship with angi- and lymphangiogenesis. Br J Cancer. 2007;1092–1100
  32. Salven P, Teerenhovi L, Joensun H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood. 1997;90:3167–3172
  33. Kini AR, Day NE, Peterson LC. Increased bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. Leukemia. 2000;14:1414–1418
  34. Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. Leuk Res. 2004;28:595–604
  35. Ho CL, Sheu LF, Li CY. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol. 2002;10:316–321
  36. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol. 2003;45:227–244
  37. Jorgensen JM, Sorensen FB, Bendix K, Nielsen JL, Olsen ML, Funder AMD, et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma. 2007;48:584–595
  38. Korkolopoulou P, Thymara I, Kavantzas N, Vassilakopoulos TP, Kokoris SI, Dmitriadou EM, et al. Angiogenesis in Hodgkin's lymphoma: a morphometric approach in 286 patients with prognostic implications. Leukemia. 2005;1:894–900
  39. Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma. Leuk Lymphoma. 2003;44:2089–2093
  40. Gratzinger D, Zhao S, Marinelli RJ, Kapp AV, Tibshirani RJ, Hammer AS, et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B cell lymphoma subtypes. Am J Pathol. 2007;170:1362–1369
  41. Ganjoo KN, Moore AM, Orazi A, Sen JA, Johnson CS, An CS. The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol. 2008;134:381–387
  42. Jørgensen JM, Sørensen FB, Bendix K, Nielsen JL, Olsen ML, Funder AM, et al. Angiogenesis in non-Hodgkin's lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma. 2007;48:584–595
  43. Gratzinger D, Zhao S, Marinelli RJ, Kapp AV, Tibshirani RJ, Hammer AS, et al. Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. Am J Pathol. 2007;170:1362–1369
  44. Sundar SS, Ganesan TS. Role of lymphangiogenesis in cancer. J Clin Oncol. 2007;25:4299–4307
  45. Nagy JA, Vasile E, Feng D, Sundberg C, Brown LF, Detmar MJ, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J Exp Med. 2002;196:1497–1506
  46. Jeltsch M, Kaipinen A, Joukov V, Meng X, Lakso M, Rauvala H, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276:1423–1425
  47. Oh SJ, Jeltsch MM, Birkenhager R, McCarthy JE, Weich HA, Christ B, et al. VEGF- and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol. 1997;188:96–109
  48. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med. 2005;201:1089–1099
  49. Pazgal I, Boycov O, Shpilberg O, Okon E, Bairey O. Expression of VEGF-C, VEGF-D and their receptor VEGFR-3 in diffuse large B-cell lymphomas. Leuk Lymphoma. 2007;48:2213–2220
  50. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, Furukawa M, et al. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved vascular endothelial growth factor production in nasopharyngeal carcinoma cells. PNAS. 2001;98:6905–6910
  51. Park S, Lee J, Ko YH, Han A, Jun HJ, Lee SC, et al. The impact of the Epstein-Barr virus status on clinical outcome in diffuse large B cell lymphoma. Blood. 2007;110:972–978
  52. Tzankov A, Heiss S, Ebner S, Sterlacci W, Schaefer G, Augustin F, et al. Angiogenesis in nodal B cell lymphomas: a high throughput study. J Clin Pathol. 2007;60:476–482
  53. Kudowaki I, Ichinohasama R, Harigae H, Ishizawa K, Okitsu Y, Kameoka J, et al. Accelerated lymphangiogenesis in malignant lymphoma: possible role of VEGF-A and VEGF-C. Br J Haematol. 2005;130:86–877
  54. Yamauchi Mai, Imajoh-Ohmi Shinobu, Shibuya Masabumi. Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci. 2007;98:1491–1497
  55. Merle B, Malaval L, Lawler J, Delmas P, Clezardin P. Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTRdependent cell adhesive site present within the N-terminal domain of thrombospondin-1. J Biochem. 1997;67:75–83
  56. Clezardin P, Lawler J, Amiral J, Quentin G, Delmas P. Identification of cell adhesive sites in the N-terminal domain of thrombospondin-1. Biochem J. 1997;321:819–827
  57. Lawler J, Ferro P, Duquette M. Expression and mutagenesis of thrombospondin. Biochemistry. 1992;31:1173–1180
  58. Ambrosini G, Adida C, Sirugo G, Altieri DC. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem. 1998;273:11177–11182
  59. Bellon G, Martiny L, Robinet A. Matrix metalloproteinases and matrikines in angiogenesis. Crit Rev Oncol Hematol. 2004;49:203–220
  60. Scarpino S, Di Napoli A, Taraboletti G, Cancrini A, Ruco LP. Hepatocyte growth factor (HGF) downregulates thrombospondin-1 (TSP-1) expression in thyroid papillary carcinoma cells. J Pathol. 2005;205:50–56
  61. YeeKO , Streit M, Hawighorst T, Detmer M, Lawler J. Expression of the type-1 repeats of thrombospondin-1 inhibits tumor growth through activation of transforming growth factor. Am J Pathol. 2004;165:541–552
  62. Rendtlew DJM, Knudsen LM, Dahl IM, Lodahl M, Rasmussen T. Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol. 2007;138:756–760
  63. Fukayama M, Ibuka T, Hayashi Y, Oaba T, Koike M, Mizutani S. Epstein-Barr virus in pyothorax-associated pleural lymphoma. Am J Pathol. 1993;143:1044–1049
  64. Timms JM, Flavell JR, Murray PG, Rickinson AB, Traverse- Glehen A, Berger F, et al. Target cells of Epstein-Barr-virus (EBV)-positive posttransplant lymphoproliferative disease: similarities to EBV-positive-Hodgkin's lymphoma. Lancet. 2003;361:217–223
  65. Horenstein MG, Nador RG, Chadburn A, Hyjek EM, Inghirami G, Knowles DM, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpes virus/human herpesvirus-8. Blood. 1997;90:1186–1191
  66. Siu LL, Chan JK, Kwang YL. Natural killer cell malignancies: clinicopathological and molecular features. Histol Histopathol. 2002;17:539–554
  67. Raphael M, Borisch B, Jaffe ES. Lymphomas associated with infection by the human immunodeficiency virus (HIV). In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. World Health Organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissues. Lyon: IARC Press; 2001;
  68. Lee OJ, Kim KW, Lee GK. Epstein-Barr virus and human immunodeficiency virus–negative oral plasmablastic lymphoma. J Oral Pathol Med. 2006;35:382–384
  69. Trivedi P, Takazawa K, Zompetta C, et al. Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression. Blood. 2004;103:313–316
  70. Hamilton-Dutoit SJ, Rea D, Raphael M, et al. Epstein-Barr virus–latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol. 1993;143:1072–1085
  71. d’Amore F, Johansen P, Houmand A, Weisenburger DD, Mortensen LS. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood. 1996;87:1045–1055
  72. Glaser SL, Gulley ML, Borowitz MJ, Craig FE, Mann RB, Stewart SL, et al. Inter and intra-observer reliability of Epstein-Barr virus detection in Hodgkin lymphoma using histochemical procedures. Leuk Lymphoma. 2004;45:489–547
  73. Kwon JM, Park YH, Kang JH, Kim K, Ko YH, Ryoo BY, et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol. 2006;85:463–468
  74. Park S, Lee , Ko YH, Han A, Jun HJ, Lee SC, et al. The impact of the Epstein-Barr virus status on clinical outcome in diffuse large B cell lymphoma. Blood. 2007;110:972–978
  75. Kuze T, Nakamura N, Hashimoto Y, Sasaki Y, Abe M. The characteristics of Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma: comparison between EBV(+) and EBV(−) cases in Japanese population. Jpn J Cancer Res. 2000;91:1233–1240
  76. Shimoyama Y, Yamamoto K, Asano N, Oyama T, Kinoshita T, Nakamura S. Age-related Epstein–Barr virus-associated B-cell lymphoproliferative disorders: Special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci. 2008;1–7
  77. Turini ME, DuBois RN. Cyclooxygenase-2A therapeutic target. Annu Rev Med. 2002;53:35–57
  78. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501
  79. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expressionin human colon cancer cells increases metastatic potential. Proc Natl Acad Sci. 1997;94:3336–3340
  80. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–716
  81. Pathak SK, Sharma RA, Steward WP, Mellon JK, Griffiths TRL, Gescher AJ. Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies. Eur J Cancer. 2005;41:61–70
  82. Tucker ON, Dannanberg AJ, Yang EK, Zhang F, Teng L, Daly JM, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987–990
  83. Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–1280
  84. TsimberidouAM , Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein- Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma. 2006;47:827–836
  85. Ladetto M, Vallet S, Trojan A, Dell’Aquilla M, Monitillo L, Rosato R, et al. Cyclooxygenase-2 is frequently expressed in multiple myeloma and is an independent predictor of poor outcome. Blood. 2005;105:4784–4791
  86. Hazar B, Ergin M, Seyrek E, Erdogan S, Tuncer I, Hakverdi S. Cyclooxygenase-2 expression in lymphomas. Leuk Lymphoma. 2004;45:1395–1399
  87. Yoshizaki T, Horikawa T, Quing-Chun R, Wakisaka H, Takeshita H, Sheen TS, et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res. 2001;7:1946–1951
  88. Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, Pagano JS. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia inducible factor 1 alpha. Mol Cell Biol. 2004;24:5223–5234
  89. Mainou-Fowler T, Overman LM, Dignum H, Wood K, Crosier S, Angus B, et al. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2. Int J Oncol. 2008 Jan;32(1):59–68
  90. Kuttler F, Valnet-Rabier MB, Angonin R, Ferrand C, Deconinck E, Mougin C, et al. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link. Leukemia. 2002 Apr;16(4):726–735
  91. Dudek AZ, Bodempudi V, Welsh BW, Jasinski P, Griffin RJ, Milbauer L, et al. Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy. Br J Cancer. 2007;97:513–522
  92. Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, et al. High-dose celecoxib and metronomic Low-dose cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clin Cancer Res. 2006;12:5190–5198
  93. Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, et al. Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 2006;47:998–1005

☆ This study has been presented at LLM meeting October 16–18, 2008 New York.

PII: S0145-2126(09)00091-5

doi: 10.1016/j.leukres.2009.02.015

Leukemia Research
Volume 33, Issue 12 , Pages 1627-1635 , December 2009

Article Tools

* Image Usage & Resolution